Online Store


Introducing AspyreRx™: The First-ever FDA-authorized Prescription Digital Therapeutic for Adults with Type 2 Diabetes

Sponsored by Better Therapeutics, this webinar will take you inside AspyreRx™, the first-ever FDA-authorized Prescription Digital Therapeutic for adults with Type 2 Diabetes (T2D).

Member Price
Non-Member Price

  • Description
  • Faculty
  • Pricing

Let us take you inside AspyreRx™, the first-ever FDA-authorized Prescription Digital Therapeutic for adults with Type 2 Diabetes (T2D). AspyreRx offers a novel form of cognitive behavioral therapy (CBT), tailored specifically for managing and treating T2D, conveniently accessible on smartphones.

Backed by extensive development and safety and efficacy data from a randomized controlled trial involving 668 participants, AspyreRx has demonstrated a statistically significant reduction in HbA1c levels and improved overall health measures.

• Discover how this digital therapeutic works, harnessing the power of technology and psychology to empower patients living with T2D.
• Gain valuable insights into the clinical data, understanding the impact AspyreRx has on managing this chronic condition.

Register today to learn how AspyreRx is empowering people with Type 2 Diabetes.

This 60-minute activity was originally presented on 12/14/2023.

Intended Audience

This activity is designed for individual or groups of diabetes care and education specialists, including nurses, dietitians, dietetic technicians, pharmacists, pharmacy technicians, nurse practitioners, clinical nurse specialists, physicians, PAs, social workers, and other health care providers interested in staying up to date on current practices of care for people with diabetes and other related conditions.


This educational program does not provide certification on the product discussed. There is no CE/CME credit for this activity.


This educational introduction to AspyreRx™ is sponsored by Better Therapeutics.


Please visit our website to learn more.

For more information on AspyreRx including prescribing information & cost and coverage, please contact Christian Meyer, Head of Sales, Better Therapeutics at [email protected] or 617-388-6074.


Elizabeth Pash, PhD, MS, RDN, LDN
Head of Medical Affairs
Better Therapeutics

Dr. Elizabeth Pash serves as Head of Medical Affairs for Better Therapeutics. She has tremendous global and national medical affairs leadership experience, as well as previous academic medical practice as the Department Head for Nutrition Therapy, at the Cleveland Clinic. Elizabeth’s experience includes Vice President of Medical Affairs for Gelesis, Head of Medical Science for Abbott Nutrition, Senior Director of Medical Affairs at Medtronic and Covidien. She has lectured throughout the U.S. and internationally on medical affairs, nutrition and relevant cardiometabolic topics. Elizabeth obtained her PhD in Health Science from Nova Southeastern University, Master of Science from the University of Akron, and Bachelor of Science from Youngstown State University.

Kara Mosesso, ANP-BC, CDCES
Lead of Population Health
Better Therapeutics

Kara Mosesso, ANP-BC, CDCES serves as the Lead of Population Health at Better Therapeutics. She is a leader in the field of lifestyle medicine and has expertise in the digital delivery of behavioral therapy to manage cardiometabolic disease. Kara has extensive clinical experience working as a board certified nurse practitioner in several academic medical centers and holds certifications as a diabetes care and education specialist (CDCES), a diplomate of the American College of Lifestyle Medicine (DipACLM), and a health coach. Kara obtained her Master of Science in Advanced Practice Nursing from Boston College and Bachelor of Science from Providence College. She is particularly passionate about leveraging digital technology to shift the healthcare paradigm to one that is more convenient, accessible, cost-effective, person-centered, and prevention-focused.


This recorded webinar is FREE for ADCES members and non-members.

Access Period

You will have access to this webinar for a period of six months after you enroll, or when the activity expires on 12/14/2025 (whichever comes first).